2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Transplantation, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Genetic Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, MDS, MPN, CML, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2831 Racial disparities in access to allogeneic stem cell transplant (ASCT) in acute myeloid leukemia (AML) are partly mediated by structural racism and health insurance.

Garth Rauscher, PhD, Ana Maria Avila Rodriguez, MD2, Anand Ashwin Patel, MD3, Melissa Larson, MD4, Hamed Youshanlouei, MD5, Sinan Cetin, MD6, Andrew Wilmington, MD7, Natalie Otto8, Kyle S.Y. Miyazaki, MD9, Nicole Altomare, MD10, Jack Shapiro, MD11, Gauri Shankar12, Mark Francis deBettencourt, MD13, Bingtao Xiang, M.D.14, Satya Manasa Kota, MBBS, MS15, Malay Mody, MPH16, Irum Khan, MD17, Stephanie B Tsai, MD18
1 University of Illinois Chicago School of Public Health, Chicago, Illinois, United States
2 University of Illinois Chicago Department of Medicine, Chicago, Illinois, United States
3 University of Chicago, Chicago, Illinois, United States
4 Rush University, Chicago, Illinois, United States
5 University of Chicago, Chicago, Illinois, United States
6 University of Chicago, Chicago, Illinois, United States
7 Rush University, Chicago, Illinois, United States
8 Rush University, Chicago, Illinois, United States
9 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
10 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
11 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
12 Loyola University Medical Center, Maywood, Illinois, United States
13 Loyola University Medical Center, Maywood, Illinois, United States
14 University of Illinois Chicago Department of Medicine, Chicago, Illinois, United States
15 University of Illinois Chicago School of Public Health, Chicago, Illinois, United States
16 University of Illinois Chicago School of Public Health, Chicago, Illinois, United States
17 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
18 Loyola University Medical Center, Maywood, Illinois, United States

BACKGROUND: Receipt of ASCT is the only curative option for the majority of AML patients (pts) and is contingent on disease control, patient comorbidities, and timely identification of a suitable donor. Underrepresentation of non-Caucasian ancestry in donor registries has partly contributed to transplant access inequities, but has been largely addressed with optimization of alternative donor transplants (cord blood, haploidentical, and mismatched). Despite increased donor availability, NCDB analysis suggests persistent inequities in transplant utilization. We examined racial and ethnic differences in the receipt, donor type, and timing of ASCT, and explored potential mechanisms underlying observed differences.

METHODS: Data came from the Chicago AML Registry of adult pts aged 18-79, diagnosed between 2012 and 2022 at six academic hospitals serving the greater Chicago region. Census tract of residence was linked to American Community Survey data to define a composite measure of structural racism (SR) based on tract racial/ethnic composition, socioeconomic disadvantage, and affluence. Pts were defined as uninsured, having public insurance only, or privately insured. We used logistic regression with marginal standardization to estimate racial/ethnic differences in ASCT receipt and donor type, and Cox proportional hazards regression to compare the timing of ASCT from diagnosis. All models were adjusted for age and gender. We compared associations before and after adjusting for potential mediators, including tract structural racism, health insurance status, body mass index, Charleson Comorbidity Index, 2017 European LeukemiaNet (ELN) risk stratification, type of induction regimen, and response to induction therapy.

RESULTS: Of 1,587 newly diagnosed AML pts aged 18-79, 44% (N=691) underwent ASCT, including 47% of non-Hispanic White (White) (492/1043), 26% of non-Hispanic Black (Black) (57/217), 44% of Hispanic (77/176), and 43% of pts of Other races/ethnicities (65/151). The prevalence of ASCT was 38%, 57%, and 37% among pts with favorable-, intermediate-, and adverse-risk ELN AML, respectively (p<0.0001). Median age at ASCT was 56 years (range 19-78 years). In multivariable models, Black pts were considerably less likely than White, Hispanic, and Other pts to receive an ASCT (25% vs. 49%, 33%, and 43%, respectively, p<0.0001). Mediation analyses revealed that tract-level SR explained 39% (p<0.0001) and 45% (p<0.0001) of the Black-White and Hispanic-White disparities in receipt of ASCT, respectively. Differences in health insurance status explained 10% (p=0.05) and 33% (p<0.0001) of the Black-White and Hispanic-White disparity. Large disparities remained within levels of insurance; most notably, there was a 29 percentage-point Black-White disparity among privately insured pts (PD = -0.29, 95% CI: -0.38, -0.19, p<0.0001).

Among pts who received an ASCT, Black pts were far more likely than White, Hispanic, or Other pts to receive an ASCT from an alternative donor (61% vs. 18%, 28%, and 26%, p<0.0001). Hispanic pts were more likely than White, Black, and Other pts to receive ASCT from a matched sibling donor (47% vs. 25% 23% and 31%, p<0.0001). Black pts were less likely than White, Hispanic, and Other pts to receive ASCT from a matched unrelated donor (16% vs. 56% 25% and 43%, p<0.0001). With respect to the timing of transplant, Black and Hispanic patients experienced longer delays: median days from diagnosis to ASCT was 197 and 188 days for Black and Hispanic vs. 138 and 139 days for White and Other pts, p=0.004) (HR=0.66, 95% CI: 0.47, 0.91, for Black and HR=0.75, 95% CI: 0.56, 0.99 for Hispanic vs. White pts). Disparities in ASCT timing were not appreciably mediated by SR or insurance.

CONCLUSION: Despite increased utilization of alternative donors, Black AML patients were less likely to undergo ASCT compared to White, Hispanic, and Other patients. Black and Hispanic patients also experienced a 2-month delay to transplant from the time of diagnosis compared to White pts. Tract-level structural racism accounted for much of the difference in receiving ASCT, while broadly defined insurance type accounted for only a modest portion of the disparity. Importantly, the large disparity in ASCT receipt among privately insured patients, who otherwise had higher rates of ASCT, suggests heterogeneity in transplant approval criteria. Ongoing analyses of potential barriers are of actionable relevance to develop targeted policy reforms.

 

Garth Rauscher, PhD: No relevant conflicts of interest to declare.